A new patent was granted from the United States Patent and Trademark Office (USPTO)

– Fundamental new patent covers new technology and design for a recombinant protein, aiming for a therapeutics development to replace plasma-derived IVIG in autoimmune disease field –

Boston, April 19, 2022 – Ab Biosciences, Inc., a biotechnology company developing biologics for chronic inflammatory and autoimmune diseases, today announced that it has received a new patent from the United States Patent and Trademark Office (USPTO, US 11,304,994), entitled, “Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use.”